Physician profile
Suzanne Cole
NPI 1598841330
$1,105.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,050 · 2022: $55.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $185.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.84 | 2021-2022 | |
| Esperion Therapeutics, INC. | $153.65 | 2021 | |
| Glaxosmithkline, LLC. | $113.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.13 | 2021-2022 | |
| Novo Nordisk INC | $79.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.79 | 2021 | |
| Lilly USA, LLC | $62.33 | 2021 | |
| Merck Sharp & Dohme LLC | $58.59 | 2021 | |
| Abbott Laboratories | $37.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.10 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.66 | 2021 | |
| Amarin Pharma, INC. | $16.91 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.